deltatrials
Completed PHASE3 NCT00554216

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35

Sponsor: Medpace, Inc.

Conditions Obesity
Interventions Placebo matched phentermine/topiramate VI-0521
Updated 7 times since 2017 Last updated: Sep 5, 2012 Started: Nov 30, 2007 Primary completion: May 31, 2009 Completion: May 31, 2009

Listed as NCT00554216, this PHASE3 trial focuses on Obesity and remains completed. Sponsored by Medpace, Inc., it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medpace, Inc.
  • VIVUS LLC
Data source: VIVUS LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Austin, United States
  • • Durham, United States
  • • Ridgefield, United States
  • • San Diego, United States
  • • Toledo, United States